Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA alkylation by methylation at O6 and N7 positions of guanine bases is a form of DNA damage primarily induced by the chemotherapeutic agent temozolomide (TMZ). The active metabolite, MTIC, transfers methyl groups to guanine bases, leading to DNA damage, cell cycle arrest, and apoptosis. The most cytotoxic lesion is O6-methylguanine, while N7-methylation is more frequent but less cytotoxic. Resistance to TMZ is often mediated by MGMT, which repairs O6-methylguanine lesions. MGMT expression levels and activity are important determinants of TMZ efficacy.
Temozolomide is a prodrug that converts to MTIC. MTIC methylates DNA at the O6 and N7 positions of guanine. O6-methylguanine mispairs with thymine leading to futile mismatch repair, double-strand breaks and apoptosis. N7-methylation can cause depurination and strand breaks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA alkylation by methylation at O6 and N7 positions of guanine bases.